Table 4 Subgroup analysis for progression-free survival, overall survival and objective response rate
Group | PFS | OS | ORR | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
No.of studies | HR (95% CI) | P | I2 (%) | No.of studies | HR (95% CI) | P | I2 (%) | No.of studies | RR (95% CI) | P | I2 (%) | |
Total | 3 | 1.06 [0.98, 1.15] | 0.13 | 0 | 8 | 0.92 [0.79–1.07] | 0.29 | 61 | 8 | 1.03 [0.93, 1.13] | 0.58 | 48 |
Nation | ||||||||||||
 USA | 1 | 1.05 [0.90, 1.22] | 0.53 | NA | 4 | 0.86 [0.77, 0.95] | 0.004 | 28 | 2 | 1.24 [1.03, 1.51] | 0.03 | 0 |
 Canada | 1 | 1.08 [0.98, 1.19] | 0.12 | NA | 2 | 1.25 [0.78, 1.98] | 0.35 | 75 | 1 | 0.91 [0.81, 1.04] | 0.16 | NA |
 Korea | 1 | 0.91 [0.64, 1.30] | 0.62 | NA | 1 | 0.70 [0.49, 0.99] | 0.04 | NA | 1 | 1.57 [0.98, 2.52] | 0.06 | NA |
 Italy | NA | NA | NA | NA | 1 | 0.94 [0.38, 2.32] | 0.89 | NA | 2 | 1.28 [0.90, 1.82] | 0.17 | NA |
 UK | NA | NA | NA | NA | NA | NA | NA | NA | 1 | 1.05 [0.35, 3.16] | 0.93 | NA |
 France | NA | NA | NA | NA | NA | NA | NA | NA | 1 | 0.89 [0.48, 1.63] | 0.70 | NA |
The number of pazopanib | ||||||||||||
 >100 | 2 | 1.07 [0.99, 1.16] | 0.1 | 0 | 3 | 0.93 [0.81, 1.06] | 0.26 | 60 | 2 | 1.05 [0.78, 1.42] | 0.73 | 85 |
 <100 | 1 | 0.91 [0.64, 1.30] | 0.62 | NA | 5 | 0.95 [0.65, 1.38] | 0.77 | 69 | 6 | 1.25 [0.96, 1.62] | 0.09 | 0 |
classification a | ||||||||||||
 Poor risk | 1 | 0.91 [0.64, 1.30] | 0.62 | NA | 2 | 0.90 [0.56, 1.44] | 0.66 | 78 | 1 | 1.57 [0.98, 2.52] | 0.06 | NA |
 Intermediate risk | NA | NA | NA | NA | 2 | 1.36 [0.73, 2.52] | 0.33 | 73 | NA | NA | NA | NA |
 Mixed group | 2 | 1.07 [0.99, 1.16] | 0.1 | 0 | 7 | 0.95 [0.82, 1.11] | 0.54 | 61 | 7 | 1.01 [0.91, 1.11] | 0.85 | 43 |
Study design | ||||||||||||
 RS | 2 | 1.07 [0.97, 1.17] | 0.17 | 0 | 7 | 0.93 [0.77, 1.12] | 0.44 | 67 | 5 | 1.17 [0.85, 1.61] | 0.33 | 58 |
 RCT | 1 | 1.05 [0.90, 1.22] | 0.53 | NA | 1 | 0.91 [0.76, 1.08] | 0.29 | NA | 3 | 1.19 [1.00, 1.43] | 0.05 | 0 |